Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Tolcapone (Tasmar) and Rytary (carbidopa/levodopa) are both medications used to treat Parkinson's disease (PD). They help manage symptoms like stiffness and slow movement. However, they belong to different medication classes. Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor, while Rytary is a combination of a dopa decarboxylase inhibitor and dopamine replacement. Tolcapone is only used as an add-on treatment with carbidopa/levodopa when symptoms aren't well-controlled, whereas Rytary can be used on its own. Both medications are taken three times daily. Tolcapone can cause serious liver damage, so regular liver monitoring is needed. Rytary can cause sleepiness, nausea, and dizziness and interacts with certain medications like MAOIs and iron.
Tolcapone (Tasmar)
Rytary (carbidopa / levodopa)
Tolcapone (Tasmar)
Rytary (carbidopa / levodopa)
Summary of Tasmar vs. Rytary
Summary for COMT inhibitor
Prescription only
Tolcapone (Tasmar) is an oral add-on medication for Parkinson's disease (PD). It's usually used when carbidopa/levodopa isn't controlling PD symptoms well enough.
Summary for Dopa decarboxylase inhibitor / Dopamine replacement
Prescription only
Rytary (carbidopa / levodopa) is a combination medication that helps treat adults with symptoms of Parkinson's disease (PD). It raises the dopamine levels in the brain to improve symptoms like stiff muscles and slowed movement. Rytary (carbidopa / levodopa) is an extended-release capsule. The typical dosage is taken by mouth three times a day. Common side effects include nausea, headache, and dizziness.
Indications of Tasmar vs. Rytary
Indications for
•Parkinson's disease (PD); as add-on treatment to carbidopa/levodopa